Evidence map›Paper›PMID 33937401›Full record

Trial reportBioMed research international2021

Application of Visual Gene Clip-Based Tailored Therapy for the Eradication of

Lili Yang, Ao Zou, Huihua Wu, Hai Guo, Fangting Zhang, Bing Zou, Junping Wang

Open access · hybridAbstract readClinical Trial
In one paragraph

Trial report in BioMed research international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Primary Antibiotic Resistance ofPathogens (Basel, Switzerland) · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Lili YangDepartment of Gastroenterology, Peking University Shenzhen Hospital, Shenzhen, Guangdong Province, 518036, China.
Ao ZouDepartment of Gastroenterology, Peking University Shenzhen Hospital, Shenzhen, Guangdong Province, 518036, China.
Huihua WuDepartment of Gastroenterology, Peking University Shenzhen Hospital, Shenzhen, Guangdong Province, 518036, China.
Hai GuoDepartment of Gastroenterology, Peking University Shenzhen Hospital, Shenzhen, Guangdong Province, 518036, China.
Fangting ZhangDepartment of Gastroenterology, Peking University Shenzhen Hospital, Shenzhen, Guangdong Province, 518036, China.
Bing ZouDepartment of Gastroenterology, Peking University Shenzhen Hospital, Shenzhen, Guangdong Province, 518036, China.
Junping WangDepartment of Gastroenterology, Peking University Shenzhen Hospital, Shenzhen, Guangdong Province, 518036, China.ORCID https://orcid.org/0000-0002-3124-3801
Peking University Shenzhen Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background

methodsThis prospective study included 244 patients (141 men and 103 women aged 20-79 years) receiving initial treatment for

results

conclusionsTailored therapy for

Indexed as

Disease EradicationAdultAgedAnti-Bacterial AgentsCytochrome P-450 CYP2C19Drug Resistance, MicrobialFemaleGenotypeHelicobacter InfectionsHelicobacter pyloriHumansMaleMiddle AgedPhenotypeProton Pump InhibitorsYoung AdultAnti-Bacterial AgentsCytochrome P-450 CYP2C19Proton Pump Inhibitors

Identifiers

PMID33937401
PMCPMC8055396
OpenAlexW3153472475

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.